0.13USD
8.31 MUSD
65.49 MUSD
62.49 M
About Protalix BioTherapeutics, Inc. (DE)
Sector
CEO
Dror Bashan
Headquarters
Hackensack
Website
Employees (FY)
208
Founded
1993
ISIN
US74365A3095
FIGI
BBG000JW08N5
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.
mid term +15,000%Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company o
$PLX - Inv SHS opportunity (EC tomorrow, BLA approval Apr27)Trigger above 5.5 (To the next resistance 5.8).
Very risky as well as catalysts opportunity movement.
Not recommended to buy or Sell PLX stocks!
Ready For A PopSteady accumulation over the last few weeks - looking ready to run with fundamentals catalysts of PDUFA and final Phase 3 data readout for PRX-102 in April
PLX Releases Phase 3 Trial Data tomorrow at 1:24 pm ESTPlease don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
$PLX - "Buy on rumor sell on news"?, Yet, BLA and BRIGHT aheadProtalix presented a good results yesterday on top line results with BRIDGE (Switch over from Refagal),
Link is below:
protalixbiotherapeutics.gcs-web.com
At this point, the main support is 5.29$ (Golden Pocket support)
Gap open below at 4.91
With expectation to the reversal .
Not recommended
$PLX - One of my faves, Creating Positive MomentumPLX Could Claim Substantial Global Market Share In Fabry Disease.
April 27, BLA approval opportunity.
Technically, resistances in rage, 4.87 and 5.2.
Support level 4.4-4.35.
Not recommended to buy or sell PLX stocks (Very risky).
Just an Idea.
$PLX - The most important year for PROTALIX Final FDA decision for BLA approval will take place on April 27.
In terms of technical aspects:
Bullish flag opportunity on sight, trigger for long with breaking above 4.74.
Main support 4.35-4.4
Not recommended to buy or sell PLX stocks.
Very risky stock and stage,
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PLX is 1.13 USD — it has decreased by 1.74% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Protalix BioTherapeutics, Inc. (DE) stocks are traded under the ticker PLX.
Protalix BioTherapeutics, Inc. (DE) is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
PLX stock is 7.34% volatile and has beta coefficient of 1.34. Check out the list of the most volatile stocks — is Protalix BioTherapeutics, Inc. (DE) there?
One year price forecast for Protalix BioTherapeutics, Inc. (DE) has a max estimate of 16.00 USD and a min estimate of 16.00 USD.
PLX earnings for the last quarter are −0.04 USD whereas the estimation was −0.07 USD which accounts for 42.86% surprise. Estimated earnings for the next quarter are −0.03 USD. See more details about Protalix BioTherapeutics, Inc. (DE) earnings.
Protalix BioTherapeutics, Inc. (DE) revenue for the last quarter amounts to 10.35 M USD despite the estimated figure of 7.65 M USD. In the next quarter revenue is expected to reach 8.15 M USD.
Yes, you can track Protalix BioTherapeutics, Inc. (DE) financials in yearly and quarterly reports right on TradingView.
PLX stock has fallen by 11.72% compared to the previous week, the month change is a 11.72% fall, over the last year Protalix BioTherapeutics, Inc. (DE) has showed a 53.11% decrease.
PLX net income for the last quarter is −6.04 M USD, while the quarter before that showed −1.85 M USD of net income which accounts for −226.35% change. Track more Protalix BioTherapeutics, Inc. (DE) financial stats to get the full picture.
Today Protalix BioTherapeutics, Inc. (DE) has the market capitalization of 84.01 M, it has increased by 4.84% over the last week.
No, PLX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PLX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Protalix BioTherapeutics, Inc. (DE) stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 208.00 employees. See our rating of the largest employees — is Protalix BioTherapeutics, Inc. (DE) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Protalix BioTherapeutics, Inc. (DE) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Protalix BioTherapeutics, Inc. (DE) stock shows the strong sell signal. See more of Protalix BioTherapeutics, Inc. (DE) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Protalix BioTherapeutics, Inc. (DE) future price: according to them, PLX price has a max estimate of 16.00 USD and a min estimate of 16.00 USD. Read a more detailed Protalix BioTherapeutics, Inc. (DE) forecast: see what analysts think of Protalix BioTherapeutics, Inc. (DE) and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Protalix BioTherapeutics, Inc. (DE) EBITDA is 11.65 M USD, and current EBITDA margin is 17.79%. See more stats in Protalix BioTherapeutics, Inc. (DE) financial statements.